Tesamorelin
Also known as: TH9507
A stabilized growth-hormone-releasing hormone (GHRH) analog and one of the few peptides here with FDA approval — indicated for reducing excess visceral fat in HIV-associated lipodystrophy.
Tesamorelin at a glance
| Name | Tesamorelin |
|---|---|
| Also known as | TH9507 |
| Category | Growth-hormone axis |
| Type | Peptide |
| Sequence | Stabilized analog of human GRF(1-44) |
| Typical dose | 2 mg once daily (clinical dosing) |
| Frequency | Daily, typically evening |
| Route | Subcutaneous injection |
| Half-life | Short — roughly 25–40 minutes, consistent with a pulsatile GH release. |
Overview
Tesamorelin is a synthetic version of the natural hormone that tells the pituitary to release growth hormone. A small chemical modification makes it more resistant to breakdown than native GHRH. Unlike most compounds in this list, it has been through large clinical trials and carries an approved indication for trimming visceral abdominal fat in people with HIV-related fat redistribution. It raises the body's own GH and IGF-1 rather than supplying GH directly.
How it’s thought to work
- Binds GHRH receptors on the pituitary, prompting release of the body's own growth hormone.
- The resulting GH pulse raises IGF-1, the downstream mediator of many GH effects.
- Preferentially reduces visceral (deep abdominal) adipose tissue in trials.
Researched uses
- Reduction of visceral fat in HIV-associated lipodystrophy (approved use)
- Investigational interest in metabolic and cognitive endpoints
Commonly cited protocol
| Typical dose | 2 mg once daily (clinical dosing) |
|---|---|
| Frequency | Daily, typically evening |
| Route | Subcutaneous injection |
| Notes | Effects on visceral fat build over weeks to months in studies. |
Reconstitution
Research vials are often 10 mg. 10 mg with 2 mL of bacteriostatic water gives 5 mg/mL, so a 2 mg dose = 0.4 mL (40 units on a U-100 syringe).
Tesamorelin dosage calculator
The calculator below is pre-filled with Tesamorelin’s commonly cited vial size and dose. Adjust the vial amount, bacteriostatic water, or dose to match your own vial — it will show the exact insulin-syringe units to draw, the concentration, and how many doses the vial holds.
Add 2 mL of bacteriostatic water to your 10 mg vial. That gives you about 5 doses of 2 mg. For each dose, draw 40 units into a 100-unit insulin syringe.
See the full Tesamorelin dosing chart (units for every dose & water amount), or open the full peptide calculator →
Cautions
- Contraindicated in pregnancy and in active malignancy.
- Can raise blood glucose / affect insulin sensitivity — monitored in clinical use.
- Prescription drug where approved; other uses are off-label or research.
Tesamorelin FAQ
What is Tesamorelin?
A stabilized growth-hormone-releasing hormone (GHRH) analog and one of the few peptides here with FDA approval — indicated for reducing excess visceral fat in HIV-associated lipodystrophy.
How does Tesamorelin work?
Binds GHRH receptors on the pituitary, prompting release of the body's own growth hormone. The resulting GH pulse raises IGF-1, the downstream mediator of many GH effects. Preferentially reduces visceral (deep abdominal) adipose tissue in trials.
What is Tesamorelin used for?
Reduction of visceral fat in HIV-associated lipodystrophy (approved use); Investigational interest in metabolic and cognitive endpoints.
What is a typical Tesamorelin dose?
2 mg once daily (clinical dosing), Daily, typically evening, Subcutaneous injection. This is a commonly cited figure for context only, not medical advice.
How do you reconstitute Tesamorelin?
Research vials are often 10 mg. 10 mg with 2 mL of bacteriostatic water gives 5 mg/mL, so a 2 mg dose = 0.4 mL (40 units on a U-100 syringe).
What is the half-life of Tesamorelin?
Short — roughly 25–40 minutes, consistent with a pulsatile GH release.